Cathy Eng
MD, FACP, FASCO
David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program
Vanderbilt-Ingram Cancer Center

Cathy Eng, MD, FACP, FASCO, Professor of Medicine, Hematology and Oncology, is the David H. Johnson Endowed Chair of Surgical and Medical Oncology, Co-Director of GI Oncology and the Co-Leader of the Gastrointestinal Cancer Research Program, Director of Strategic Relations, Executive Director of the Young Adults Cancers Program. She was the Ambassador for the American Cancer Society ResearcHERS campaign (2020-2022). She is currently the Director for Strategic Relations. She is a highly sought mentor and served on the Vanderbilt-Ingram Mentorship Council and is currently a mentor on the T-32 grant and serves on the Professional Development Mentor. She continues to assume leadership positions devoted to development of phase I-III clinical trials using novel therapeutics for biomarker discovery and enhanced drug utilization in colorectal, appendiceal and anal cancer patients.

Nationally, Dr. Eng has also been highly active serving on multiple committees for ASCO, ECOG, and SWOG. She was chosen for the ASCO Leadership Development Program, ASCO Social Media Committee, the ASCO Colorectal Guidelines Committee, ASCO Scientific Program Committee (Colorectal Cancer Track) and the ASCO Communications Committee. She has served as the co-chair of the SWOG Rectal/Anal Cancer Subcommittee; the Vice-Chair for the SWOG GI Committee; the Chairman of the NCI Rectal/Anal Task Force, NCI GI Steering Committee, and is now the co-Chair of the NCI GI Steering Committee. She participated in the President Biden'ts Cancer Moonshot White House Colorectal Cancer Forum.

She has published in many peer-reviewed journals and served on many national grant review panels.

Sessions

Register
General Session

Welcome

Friday, May 17, 2024
9:15 AM - 9:25 AM
General Session

Session 1: Debate: Best Targeted Therapy for First-Line Gastroesophageal Cancer: PD-1 Inhibitors or Claudin-18.2 (CLDN18.2)? DISCUSSION

Friday, May 17, 2024
9:55 AM - 10:05 AM
General Session

Session 2: Debate: MSI Tumors: Does Anatomic Location Affect the Management? Yes vs No: DISCUSSION

Friday, May 17, 2024
10:35 AM - 10:45 AM
General Session

Session 3: Debate: Management of Gastric Cancer With Limited Peritoneal Carcinomatosis - Cytoreduction and HIPEC for All: Yes vs No - DISCUSSION

Friday, May 17, 2024
11:45 AM - 11:55 AM
General Session

Session 6: Debate: Germline Testing for Gastrointestinal Tumors for all Irrespective of Tumor Origin: Yes vs No - DISCUSSION

Friday, May 17, 2024
2:55 PM - 3:05 PM
General Session

Session 7: Debate: Is ctDNA Ready for Prime Time for Detection of Molecular Residual Disease? Yes vs No - DISCUSSION

Friday, May 17, 2024
4:45 PM - 4:55 PM
General Session

Session 8: Debate: Is There A Role for Immune Checkpoint Inhibition Outside of A Clinical Trial in Microsatellite Stable (MSS) Patients? Yes vs No - DISCUSSION

Friday, May 17, 2024
5:25 PM - 5:35 PM
General Session

Welcome

Saturday, May 18, 2024
8:00 AM - 8:05 AM
General Session

Session 9: Debate: Transarterial Chemoembolization for Hepatocellular Carcinoma with Immune Checkpoint Blockade: Skip it or Do it? DISCUSSION

Saturday, May 18, 2024
8:35 AM - 8:45 AM
General Session

Session 10: Debate: Cholangiocarcinoma - Immune Checkpoint Blockade for All: Yes vs No - DISCUSSION

Saturday, May 18, 2024
9:15 AM - 9:25 AM